CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,167 enrolled
Drug / intervention
FORTEOdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01078805
NCT01078805N/ACompleted
CompareCT.gov

Direct Assessment of Non-Vertebral Fractures in Community Experience (DANCE)

Eli Lilly and Company·observational·Posted Mar 2, 2010·Updated Jun 26, 2012

In Brief

An observational study evaluating FORTEO for Osteoporosis. Completed, enrolled 4,167 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the long-term effectiveness, safety, and tolerability of FORTEO in a larger, more diverse "real world" population than studied in clinical trials

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2, 2010
Enrollment StartAug 1, 2003
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 16.3 years ago

Interventions

FORTEOdrug

prescribed in accordance with usual clinical practice for up to 24 months